Home > Formulary : Paediatric > Paediatric Chapters > 10. Musculoskeletal and joint diseases >
BNSSG Paediatric Joint Formulary
10.2 Neuromuscular disorders
Last edited: 31-01-2024
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
10.2.1 Myasthenia gravis
Anticholinesterases
Neostigmine (TLS Red)
- Only on the recommendation of a Consultant Neurologist
Pyridostigmine (TLS Red)
- Only on the recommendation of a Consultant Neurologist
10.2.2 Spasticity
Gamma-aminobutyric Acid Analogues and Derivatives
Baclofen (intrathecal) (TLS Red)
- Baclofen may lead to reversible neurological changes and coma in people with low kidney function. Start at very low doses at very long intervals in these patients and titrate to effect
- Refer to the NHS England Policy D04/P/c: Intrathecal baclofen (ITB)
- For Intrathecal baclofen use please refer to the BNSSG Prior Approval Form - Continuous Intrathecal Baclofen Infusion. This needs to be completed and approved prior to initiation